Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Stock Quote Today & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

By working with Health Canada and the FDA to approve the optimization of the clinical study design, analysis and reporting structure of Study II early in the process, Theralase® is able to much better align the clinical data collected in Study II with best practices and current expectations of the Canadian and US regulators; thereby, helping to avoid difficult to address questions at final review time

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer

Current News (TSXV:TLT)

Theralase advances cancer research after private placement

Jonathon Brown 1 day ago

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

Accesswire 1 day ago

This company’s Photo Dynamic Therapy is transforming cancer treatment

Jocelyn Aspa April 9, 2024

Theralase patents new cancer vaccine in Canada

Trevor Abes  April 5, 2024

Theralase(R) Granted Canadian Cancer Vaccine Patent

Accesswire April 5, 2024

Theralase(R) Release's 4Q2023 Interim Financial Statements

Accesswire March 27, 2024
View More News ››

To date, the Theralase® Study II clinical data has demonstrated best-in-class performance for a single agent, providing high efficacy, durable response and a high safety profile, with no serious adverse events directly related to RuvidarTM or the TLC-3200 Medical Laser System

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer

Opinion & Analysis (TSXV:TLT)

Pharmaceutical company treats bladder cancer with new tech

Ryan Dhillon January 8, 2024

Theralase is raising up to $5.3M to complete bladder cancer study

Coreena Robertson November 6, 2023

For Better or Worse? On the Verge of a New Era in Investing

Stockhouse Editorial April 1, 2021

Buzz on the Bullboards: A Big Picture Look at Small-Cap Opportunities

Stockhouse Editorial February 18, 2021

Buzz on the Bullboards: Tracking the Big Movers of 2020

Stockhouse Editorial December 17, 2020

Buzz on the Bullboards: T’is the Season for a Rebound?

Stockhouse Editorial December 3, 2020
View More Opinion ››

Bullboard Posts (TSXV:TLT)

RE:RE:RE:RE:RE:April 29, Next Monday expecting an annual report, will see

They accepted my money. I'm a drop of water in the lake. Hilles
hilles - 39 minutes ago

RE:RE:RE:RE:RE:April 29, Next Monday expecting an annual report, will see

Hahahaha don't tell the good ole boys club that, u might get sued!
Dumbeldorfwhite - 47 minutes ago

RE:RE:RE:RE:RE:RE:RE:April 29, Next Monday expecting an annual report, will see

Somebody having a field day after the announced  pp Historical Short Volume Data for TLTFF Date Close ...
Alamir1111 - 59 minutes ago

RE:RE:RE:RE:RE:RE:April 29, Next Monday expecting an annual report, will see

Ibrx in 2 days of trading after receiving btd gained  approximately 10%  $5.16 0.3399 |  7.05%...
Alamir1111 - 1 hour ago

RE:RE:RE:RE:RE:April 29, Next Monday expecting an annual report, will see

AUG 2019 warrants expiring  2024.That's a huge nr  4 monts to go. Company issued 57,500,000 units of the Company ...
Alamir1111 - 1 hour ago

RE:RE:RE:RE:April 29, Next Monday expecting an annual report, will see

May I as respectfully as possible ask anyone thinking the company turned anyone's money away to please pull their head out of the...
CAinPlap - 1 hour ago
View more Bullboard ››

Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250